Acquisition Synergies Position WaferGen’s single-cell and library-prep platforms alongside Takara Bio USA’s existing customer base to accelerate cross-sell opportunities across clinical labs, academia, and pharma. Leverage the acquisition to present end-to-end workflows that combine ICELL8 single-cell isolation with Takara-compatible reagents and sequencing-ready libraries, expanding bundle offerings and accelerating adoption.

Cross-Sell Platform Unlock cross-sell opportunities by pairing ICELL8, SmartChip, and Apollo within Takara’s global sales network. Focus on labs performing single-cell analyses, biomarker validation, and targeted sequencing to deliver a complete solution from single-cell isolation to NGS library preparation.

Clinical Lab Targeting Target clinical laboratories and contract research organizations that require scalable, high-throughput library preparation and biomarker profiling. Promote SmartChip and Apollo as turnkey options for rapid NGS library prep and biomarker validation, encouraging pilots in oncology, neuroscience, and pulmonary research.

Global Channel Leverage Leverage Takara Bio USA’s international distribution to reach universities, biopharma, and contract service providers worldwide. Tailor messaging to regulatory-compliant workflows and highlight cost/time savings from integrated single-cell and NGS-ready library workflows.

Bundled Solutions Offer bundled solutions that integrate WaferGen’s ICELL8, SmartChip, and Apollo with Takara reagents and kits to create a seamless, end-to-end single-cell genomics workflow for R&D and clinical labs. Emphasize speed, throughput, and reproducibility to win larger multi-site deals.